|
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical research trials and A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. clinical trial. Human subjects often obtain the finest healthcare possible for their A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas. condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.  A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
For Condition: Pancreatic Neoplasms,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Pancreas cancer that cannot be removed by surgery OR that has spread to a new site in your body. - You must have one tumor that can be physically measured or scanned by the doctor. - You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU. - You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis. Exclusion Criteria: - Treatment with any medication or device that has not been approved by regulatory agencies, like the FDA, at the time you enter the study. - Documentation that the cancer has spread to your brain. - Pregnant or breastfeeding. - A second primary cancer. - Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 5148;
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035035
Other Pancreatic Neoplasms Studies:
1. A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
2. Mistletoe Extract and Gemcitabine for the Treatment of Solid Tumor Cancers
3. Magnetic-Targeted Doxorubicin in Treating Patients with Cancer Metastatic to the Liver
4. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
5. A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Related Studies:
Other Pancreatic Neoplasms Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
|
|
|
|
|
|
|
|
